ReviewPlatelets2010
CalDAG-GEFI and platelet activation.
Review in Platelets, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- α, δ‑ACS pharmacology & translational science · 2025Article
- Involvement of platelet signaling pathways in colorectal cancer and new therapeutic targets.American journal of cancer research · 2024Review
- CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors.Neurobiology of disease · 2021Article
- Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- The road to ERK activation: Do neurons take alternate routes?Cellular signalling · 2020Review
- Integration of Rap1 and Calcium Signaling.International journal of molecular sciences · 2020Review
- Platelets Are at the Nexus of Vascular Diseases.Frontiers in cardiovascular medicine · 2019Review
- The role of P2YCellular and molecular life sciences : CMLS · 2019Review
- JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.The Journal of clinical investigation · 2018Article
- Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis.Platelets · 2018Article
- Importance of the REM (Ras exchange) domain for membrane interactions by RasGRP3.Biochimica et biophysica acta. Biomembranes · 2017Article
- A negative-feedback loop regulating ERK1/2 activation and mediated by RasGPR2 phosphorylation.Biochemical and biophysical research communications · 2016Article
- Structural Basis for the Failure of the C1 Domain of Ras Guanine Nucleotide Releasing Protein 2 (RasGRP2) to Bind Phorbol Ester with High Affinity.The Journal of biological chemistry · 2016Article
- CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2016Article
- RASA3 is a critical inhibitor of RAP1-dependent platelet activation.The Journal of clinical investigation · 2015Article
- Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- Platelets and cancer: a casual or causal relationship: revisited.Cancer metastasis reviews · 2014Review
- P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.Purinergic signalling · 2012Review
- Protein kinase C mediates platelet secretion and thrombus formation through protein kinase D2.Blood · 2011Article
- Emerging roles of store-operated Ca²⁺ entry through STIM and ORAI proteins in immunity, hemostasis and cancer.Channels (Austin, Tex.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Rapid activation of platelets at sites of vascular injury is a critical event in thrombosis and hemostasis. Here, we review recent findings, which (a) identified CalDAG-GEFI (RasGRP2) at the nexus of the rapid Ca(2+)-dependent platelet activation, (b) demonstrated a complex synergy between signaling provided by CalDAG-GEFI, protein kinase C and the Gi-coupled receptor for ADP, P2Y12, and (c) suggested CalDAG-GEFI as a novel target for anti-platelet therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.